ADMA

ADMA Biologics Inc

10.84 USD
+0.22 (+2.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ADMA Biologics Inc stock is up 12.92% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
23 May 15:48 21 Jun, 2024 7.50 CALL 158 602
28 May 13:44 15 Nov, 2024 5.00 CALL 90 62
28 May 17:54 16 Aug, 2024 5.00 CALL 73 2344
31 May 15:29 20 Dec, 2024 7.50 CALL 100 759
03 Jun 13:38 20 Dec, 2024 7.50 CALL 100 759
03 Jun 13:40 20 Dec, 2024 7.50 CALL 121 759
05 Jun 17:28 16 Aug, 2024 7.50 CALL 100 4125
07 Jun 15:53 17 Jan, 2025 15.00 CALL 500 10
07 Jun 17:38 16 Aug, 2024 5.00 CALL 65 2343
18 Jun 18:41 16 Aug, 2024 5.00 CALL 100 2321

About ADMA Biologics Inc

ADMA Biologics, Inc. engages in developing, manufacturing, and marketing specialty plasma-derived biologics. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI) and ASCENIV. Nabi-HB for the. treatment of acute exposure to blood containing Hepatitis B surface antigen.